Otros idiomas Genome & Company

Acciones

A314130

KR7314130006

Precio de cierre Korea S.E. Otros sitios de cotización 00:00:00 13/05/2024			Varia. Cinco días.	Varia. 1 de enero.
7.120 ^KRW	-0,84 %		+3,04 %	-42,99 %

24/01	Genome & Company anuncia resultados de primera línea positivos del ensayo clínico de fase 2 de la combinación de GEN-001 y Bavencio®? para el tratamiento del cáncer gástrico Póster presentado en ASCO GI	CI
2023	Genome & Company anuncia resultados positivos del análisis provisional del ensayo de fase II Gen-001 más avelumab (Bavencio®?)	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio®? for the Treatment of Gastric Cancer Poster Presented at ASCO GI	24/01
Genome & Company Announces Positive Results from Interim Analysis of Gen-001 Plus Avelumab (Bavencio®?) Phase II Trial	19/05/23
Genome & Company announced that it has received KRW 23 billion in funding from a group of investors	07/04/23
Genome & Company announced that it expects to receive KRW 23 billion in funding from a group of investors	05/04/23
Genome & Company announced that it has received KRW 34.34975035 billion in funding from a group of investors	02/09/22
Genome & Company announced that it expects to receive KRW 34.34975035 billion in funding from a group of investors	18/08/22
Genome and Company Announces Clinical Trial Collaboration with Merck & Co., Inc	04/03/22
Microbiome CDMO, List Labs, Partners with Genome And Company, to Create Global Microbiome Research, Development, and Manufacturing Powerhouse	21/09/21
Genome & Company(KOSDAQ:A314130) added to S&P Global BMI Index	20/09/21
Genome & Company agreed to acquire a 60% stake in List Biological Laboratories, Inc. for $27 million.	08/09/21
Genome and Company Signs Second Clinical Trial Collaboration and Supply Agreement (Phase 2) with Merck Kgaa, Darmstadt, Germany and Pfizer for Immuno-Oncology Microbiome Study	09/03/21
Genome & Company and Debiopharm Join Forces to Create New Highly Specific Therapies for Cancer Patients	25/02/21
Genome & Company Announces First Patient Dosed in Phase 1/1B Study of GEN-001	27/10/20
Genome & Company announced that it expects to receive KRW 19.99999001 billion in funding from Korea Development Bank, Investment Arm	26/08/20
Scioto Biosciences, Inc. announced that it has received $26.5 million in funding from Genome & Company and other investors	11/08/20
Scioto Biosciences, Inc. announced that it expects to receive $6.50074 million in funding	07/08/20
Genome & Company announced that it has received KRW 4.00002 billion in funding	25/06/20
Genome & Company announced that it expects to receive KRW 4.00002 billion in funding	17/06/20
Genome & Company announced that it has received KRW 3.62991 billion in funding	24/04/20
Genome & Company Receives FDA IND Clearance for GEN-001, its First Anti-Cancer Microbiome Therapeutic	20/04/20

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Genome & Company

Acciones

A314130

KR7314130006

Otros idiomas

Filtros